Study #2023-0859
Phase 1 study of intratumoral administration of JNJ-87704916, an oncolytic virus, as monotherapy and in combination for advanced solid tumors.
MD Anderson Study Status
Enrolling
Treatment Agent
JNJ-87704916, Cetrelimab
Description
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumors
Study phase:
Phase I
Physician name:
Sarina Piha-Paul
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-866-967-2182
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.